Wave Life Sciences USA, Inc.

14 clinical trials · Sponsor

Record	Firm	Date
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (NCT07209332)	Wave Life Sciences USA, Inc.	2025-12-28
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity (NCT06842186)	Wave Life Sciences USA, Inc.	2025-01-31
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD (NCT06405633)	Wave Life Sciences USA, Inc.	2024-07-19
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (NCT06186492)	Wave Life Sciences USA, Inc.	2023-11-14
Study of WVE-003 in Patients With Huntington's Disease (NCT05032196)	Wave Life Sciences USA, Inc.	2021-09-06
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (NCT04931862)	Wave Life Sciences USA, Inc.	2021-06-28
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (NCT04617847)	Wave Life Sciences USA, Inc.	2020-04-13
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (NCT04617860)	Wave Life Sciences USA, Inc.	2019-09-24
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (NCT03907072)	Wave Life Sciences USA, Inc.	2019-09-04
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy (NCT03508947)	Wave Life Sciences USA, Inc.	2018-01-24

Track Wave Life Sciences USA, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.